CN106420698A - Application of vitexin to preparation of medicines for prevention and/or treatment of malignant tumors - Google Patents
Application of vitexin to preparation of medicines for prevention and/or treatment of malignant tumors Download PDFInfo
- Publication number
- CN106420698A CN106420698A CN201610980214.9A CN201610980214A CN106420698A CN 106420698 A CN106420698 A CN 106420698A CN 201610980214 A CN201610980214 A CN 201610980214A CN 106420698 A CN106420698 A CN 106420698A
- Authority
- CN
- China
- Prior art keywords
- vitexin
- injection
- tumor
- medicine
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Dermatology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention belongs to the technical field of antitumor medicines and relates to application of vitexin to preparation of medicines for prevention and/or treatment of malignant tumors. A structural formula I of the vitexin is as shown in the specification. The medicines prepared from the vitexin are excellent in malignant tumor resistance.
Description
Technical field
The present invention relates to the technical field of antineoplastic is and in particular to a kind of Vitexin in preparation prevention and/or is treated
Application in malignant tumor medicine.
Background technology
Lung cancer is that M ＆ M increases the soonest, one of malignant tumour maximum to population health and life threat.
In prior art, lung cancer therapy process is frequently with doctor trained in Western medicine chemotherapeutics and Chinese medicine.Conventional treatment non-small cell lung cancer good effect
Chinese medicine have blood stasls syndrome, beneficial lung Qinghua particle, clearing lung-heat Sanjie Pill etc.；The conventional eutherapeutic Chinese medicine for the treatment of ED-SCLC has
Beneficial lung Qinghua cream, beneficial lung Qinghua particle, clearing lung-heat Sanjie Pill etc..
Leaves of Hawthorn (Crataegus pinnatifida) belongs to rosaceous plant, and taste is sour, mild-natured, return liver warp, and primary efficacy is
Promoting blood circulation and removing blood stasis, qi-regulating is promoted blood circulation, and for qi depression to blood stasis, chest distress, palpitation and amnesia, dizziness and tinnitus, is in Chinese medicine drug for invigorating blood circulation and eliminating stasis
One of important medicine.Modern medicine study proves that leaves of Hawthorn has the effect such as cardiac stimulant, step-down, antianginal and reducing blood lipid.Mesh
Front to leaves of Hawthorn most study, the most extensive and the most deep be in terms of cardiovascular effect, clinically can be used for treating coronary disease
Disease, angina pectoris, hyperlipidemia, arrhythmia cordis etc..
The chemical research of leaves of Hawthorn shows, in leaves of Hawthorn, main active component is Flavonoid substances.Master in leaves of Hawthorn
Flavones is wanted to have nearly 20 kinds of Vitexin, Kaempferol, Quercetin, vitexin rhamnopyranoside and Vitexin glycoside etc..Publication No.
The Chinese patent of CN1300164 discloses a kind of extracting method of Vitexin, purposes and preparation, isolates single from leaves of Hawthorn
Active ingredient Vitexin so as to purity reaches more than 98%, for angiocardiopathy field, effect is significant.But in prior art
Report Vitexin is not in treatment malignant tumour, the especially application in lung cancer, sarcoma.
Content of the invention
It is an object of the invention to provide a kind of Vitexin answering in preparation prevention and/or treatment malignant tumor medicine
With Vitexin is good for the therapeutic effect of malignant tumour, work fast, and toxic and side effect is low, there is provided a kind of Vitexin new
Purposes.
The invention provides the application in a kind of Vitexin preparation prevention and/or treatment malignant tumor medicine, described Vitex negundo var cannabifolia
The structure of element is as shown in formula I：
Preferably, described malignant tumour is lung cancer tumor, sarcoma.
Preferably, described lung cancer is small cell lung cancer tumor.
Preferably, the formulation of described medicine is injection.
Preferably, described medicine also includes auxiliary material, and described auxiliary material includes mannitol, NaOH, hydrochloric acid.
Preferably, the dosage of described medicine is 3mg/ time～60mg/ time.
The Vitexin preparation that the present invention provides prevents and/or treats the application in malignant tumor medicine, using the teaching of the invention it is possible to provide a kind of
The active drug of anti-malignant tumor, work fast good to lung cancer or sarcoma therapeutic effect, toxic and side effect low it is achieved that to male
Jing Su preferably applies.
Specific embodiment
The invention provides the application in a kind of Vitexin preparation prevention and/or treatment malignant tumor medicine, described Vitex negundo var cannabifolia
The structure of element is as shown in formula I：
In the present invention, described Vitexin extracting and developing preferably from leaves of Hawthorn, obtains single active ingredient Vitexin,
Its purity is made to reach more than 98%.The present invention does not have special restriction to described extraction separation and purification method, using this area skill
The extraction separation and purification method of the Vitexin known to art personnel, is such as preferably entered to Vitexin by hydrolysis, crystallization, recrystallization
Row extracts.
In the present invention, described malignant tumour is preferably lung cancer tumor, sarcoma.
In the present invention, described lung cancer is preferably ED-SCLC.
In the present invention, the formulation of described medicine is preferably injection.
In the present invention, described medicine also includes auxiliary material, and described auxiliary material includes mannitol, NaOH, hydrochloric acid.
In the present invention, the dosage of described medicine is 3mg/ time～60mg/ time.
The present invention does not have special restriction to the preparation of described injection medicine, using note well known to those skilled in the art
Penetrate the preparation method of agent.Preparation method as described injection is preferably：Weigh mannitol, Vitexin mixing, filling is penetrated
With water, stir, repeated hydrogenation sodium hydroxide solution is dissolved, then be adjusted to pH value for 8.0～9.0 with hydrochloric acid, plus pin activity
Charcoal, stirs 10～15min, micropore titanium filter decompression coarse filtration, de- charcoal, after checking that content, pH are qualified, then through miillpore filter terminal
After filtration, it is sub-packed in cillin bottle, frozen drying, carries out follow-up pre-freeze, drying and packaging, obtain vitexin injection
Product.
In the Vitexin preparation prevention present invention being provided with reference to specific embodiment and/or treatment malignant tumor medicine
Application be further described in detail, technical scheme includes but is not limited to following examples.
Embodiment 1
The preparation of vitexin injection
A, weigh Vitexin 3g, mannitol 180g raw material uniformly mixes, plus 600ml water for injection, stir, then plus
The sodium hydroxide solution 1500ml of 0.1mol/L, stirring and dissolving, then it is adjusted to PH for 8.5 with the hydrochloric acid solution of 1mol/L, filling is penetrated
With water to 3000ml, the needle-use activated carbon plus 0.05%, stir 10min, micropore titanium filter decompression coarse filtration, de- charcoal, inspection contains
After amount, pH are qualified, then after 0.22 μm of miillpore filter end-filtration, it is sub-packed in 10ml cillin bottle, often bottled 3ml, low temperature cold
Lyophilized dry.
B, pre-freeze：The medicine having dispensed is put into pre-freeze on freeze drying box internal partition start to+25 DEG C～-40 DEG C, 2 hours；-
40 DEG C, 3 hours.
C, lyophilization：Condenser temperature is dropped to less than -45 DEG C, starts vavuum pump, treat that vacuum reaches a fixed number
After value, slowly open butterfly valve, close refrigerator below when the vacuum in drying box reaches 13.33Pa (0.1mmHg), by dividing plate
Under heating system slowly heat, so that the temperature of frozen product is gradually risen to -20 DEG C, then gradually risen to 25 DEG C by -20 DEG C.
Whole lyophilization process about 26 hours.
D, re-dry：It is dried 5 hours at 25 DEG C, loss on drying meets regulation, aseptically adds a cover plug, rolls
Lid, packaging, inspection, warehouse-in.
Embodiment 2
The preparation of vitexin injection
A, weigh Vitexin 30g, mannitol 180g raw material uniformly mixes, plus 600ml water for injection, stir, then plus
The sodium hydroxide solution 1500ml of 0.1mol/L, stirring and dissolving, then it is adjusted to PH for 8.5 with the hydrochloric acid solution of 1mol/L, filling is penetrated
With water to 3000ml, the needle-use activated carbon plus 0.05%, stir 10min, micropore titanium filter decompression coarse filtration, de- charcoal, inspection contains
After amount, pH are qualified, then after 0.22 μm of miillpore filter end-filtration, it is sub-packed in 10ml cillin bottle, often bottled 3ml, low temperature cold
Lyophilized dry.
B, pre-freeze：The medicine having dispensed is put into pre-freeze on freeze drying box internal partition start to+20 DEG C～-40 DEG C, 3 hours；-
40 DEG C, 4 hours.
C, lyophilization：Condenser temperature is dropped to less than -45 DEG C, starts vavuum pump, treat that vacuum reaches a fixed number
After value, slowly open butterfly valve, close refrigerator below when the vacuum in drying box reaches 13.33Pa (0.1mmHg), by dividing plate
Under heating system slowly heat, so that the temperature of frozen product is gradually risen to -15 DEG C, then gradually risen to 30 DEG C by -15 DEG C.
Whole lyophilization process about 30 hours.
D, re-dry：It is dried 4 hours at 25 DEG C, loss on drying meets regulation, aseptically adds a cover plug, rolls
Lid, packaging, inspection, warehouse-in.
Embodiment 3
The preparation of vitexin injection
A, weigh Vitexin 60g, mannitol 240g raw material uniformly mixes, plus 600ml water for injection, stir, then plus
The sodium hydroxide solution 1500ml of 0.1mol/L, stirring and dissolving, then it is adjusted to PH for 8.5 with the hydrochloric acid solution of 1mol/L, filling is penetrated
With water to 3000ml, the needle-use activated carbon plus 0.05%, stir 10min, micropore titanium filter decompression coarse filtration, de- charcoal, inspection contains
After amount, pH are qualified, then after 0.22 μm of miillpore filter end-filtration, it is sub-packed in 10ml cillin bottle, often bottled 3ml, low temperature cold
Lyophilized dry.
B, pre-freeze：The medicine having dispensed is put into pre-freeze on freeze drying box internal partition start to+25 DEG C～-40 DEG C, 2 hours；-
40 DEG C, 3 hours.
C, lyophilization：Condenser temperature is dropped to less than -45 DEG C, starts vavuum pump, treat that vacuum reaches a fixed number
After value, slowly open butterfly valve, close refrigerator below when the vacuum in drying box reaches 13.33Pa (0.1mmHg), by dividing plate
Under heating system slowly heat, so that the temperature of frozen product is gradually risen to -20 DEG C, then gradually risen to 25 DEG C by -20 DEG C.
Whole lyophilization process about 26 hours.
D, re-dry：It is dried about 5 hours at 25 DEG C, loss on drying meets regulation, aseptically adds a cover plug, rolls
Lid, packaging, inspection, warehouse-in.
Embodiment 4
Vitexin injection is to murine sarcoma S180Tumor-inhibiting action.
Method：
1st, take tumour by intraperitoneal inoculation murine sarcoma S180The kunming mice cervical dislocation of cell one week after is put to death, and uses the tincture of iodine
With 75% (v/v) ethanol belly partly sterilised, aseptically take out ascites, with 3 times of normal saline dilution, obtain knurl liquid.
2nd, inoculation knurl liquid gives every mouse armpit subcutaneous accurate inoculation knurl liquid 0.2ml.Noting inoculating position each group should one
Cause, subcutaneous for preventing knurl liquid from spilling after inoculating, usually from chest or skin of back inserting needle, reach oxter.
3rd, next day after packet administration inoculation, by animal random packet, weigh, vitexin injection sets three dosage groups, point
Not Wei 3,6,12mg/kg；Set positive control (endoxan) and negative control (physiological saline), every group of 10 animals simultaneously.Male
Chaste tree essence injecta presses 3,6, tri- dosage groups of 12mg/kg with equal-volume (0.2ml) variable concentrations to animal lumbar injection, daily one
Secondary, successive administration 7 days, positive controls after inoculation next day with 100mg/kg dosage to animal intraperitoneal injection of cyclophosphamide 1 time,
Once a day, negative control group is that one time a day, each 0.2ml.
4th, claim 24 hours after knurl weight last dose, cervical dislocation puts to death animal, weighs respectively, calculate tumor control rate,
Carry out therapeutic evaluation, and each group result is carried out statistical procedures.Solid tumor is using the evaluation tumor weight of every group of animal as treatment
Effect index.
Calculate the average knurl weight of control group and the ratio (T/C-%) of the average knurl weight for the treatment of group, also can calculate tumour growth
Inhibiting rate (%), computing formula is as follows：
Inhibition rate of tumor growth %=(the average knurl weight of the average knurl weight-treatment group of the control group) average knurl weight × % of/control group
Result：Vitexin injection is to murine sarcoma S180There is stronger inhibitory action, the inhibiting rate of 12mg/kg is
55.7% (P ＜ 0.05), the results are shown in Table 1:
Table 1 inoculation medicine is to sarcoma S180Mouse Weight and knurl weight impact (N=10)
Compare with control group：* P ＜ 0.05, * * P ＜ 0.01
As shown in Table 1, the impact to Mouse Weight and knurl weight for the Vitexin is all statistically significant, and in 12mg/kg dosage
Reach good effect, be not less than positive control drug.
Embodiment 5
The inhibitory action that vitexin injection grows to Mice Bearing Lewis Lung Cancer
Principle：Allogenic animal transplanted tumor model system selects the mouse of three kinds or more, rat implantation tumour,
Carry out experimental therapy.Physical inspection tumor-like hyperplasia or T/C%, method of administration should be consistent with clinic, and set three or three with
Upper dosage group.The result of repeatability should be obtained to the experimental therapy of each knurl strain, vitexin injection moves to allogenic animal
Plant property tumour has certain growth inhibition effect.
Material：Animal：C57BL/6 mouse.Knurl strain：Mice Bearing Lewis Lung Cancer.Equipment：Scalpel, cut, tweezers, syringe, glass
Glass homogenizer or trochar, superclean bench.Medicine and reagent：Vitexin injection is tested front physiological saline and is made into medicine
The solution of desired concn, the solution that front normal saline dilution becomes desired concn tested by fluorouracil (5-Fu).
Method：
1. take the good knurl source of knurl kind mice transplanted tumor Lewis lung cancer growth, under aseptic condition, take tumor animal
Solid tumor mass, subtract into fine grained chippings with scissors, with trochar transplanting or glass homogenizer add SPSS and wear into homogenate,
Count the oncocyte number in every 1ml homogenate.
2. inoculation knurl liquid gives every animal subcutaneous vaccination 2 × 106Cell.
3. packet administration inoculation packet administration in latter 24 hours, every group of 10 animals.Experiment is divided into 5 groups, 1. negative control group,
2. fluorouracil positive drug control group, 3. vitexin injection small dose group 3mg/kg, 4. vitexin injection middle dose group
6mg/kg, 5. vitexin injection high dose group 12mg/kg.Fluorouracil 25mg/kg next day gastric infusion, altogether to 3 times.Vitex negundo var cannabifolia
The daily gastric infusion of essence injecta 1 time, continuous 10 days.
4. put to death animal, weigh and shell knurl and weigh within 24 hours after claiming knurl weight last dose, calculating inhibiting rate, and united
Processing data learned by meter.Calculate inhibition rate of tumor growth (%), computing formula is as follows：
Inhibition rate of tumor growth %=(the average knurl weight of the average knurl weight-administration group of control group) the average knurl weight of/control group ×
100%
Result：Vitexin injection, in the dosage of 3mg/kg, 6mg/kg, 12mg/kg, all has to Mice Bearing Lewis Lung Cancer
Certain inhibitory action, and be in dose-effect relationship.Illustrate that vitexin injection has certain antitumor action, result such as table
Shown in 2.
Table 2 Mice Bearing Lewis Lung Cancer growth inhibition situation (x ± s, n=10)
| Group | Dosage (mg/kg) | Body weight (g) beginning/end | Knurl weight (g) | Inhibiting rate (%) |
| Comparison | -- | 20.2/+2.1 | 3.00±0.68 | -- |
| 5-Fu | 25 | 20.0/+5.7 | 1.50±0.62 | 50.0** |
| Vitexin injection | 3 | 21.2+4.3 | 2.11±0.87 | 30** |
| Vitexin injection | 6 | 20.4+7.3 | 1.62±0.94 | 46** |
| Vitexin injection | 12 | 20.5+6.5 | 1.51±0.86 | 50** |
With control group ratio：* P ＜ 0.01
As shown in Table 2, vitexin injection has obvious effect to Mice Bearing Lewis Lung Cancer growth inhibition, statistically significant,
And reach good effect in 12mg/kg dosage, it is not less than positive control drug.
Embodiment 6
The growth inhibition effect to human small cell lung carcinoma transplanted tumor in nude mice for the vitexin injection
Raw material：Nude mice, also known as athymic mouse, has four features：1. congenital thymic disappearance, 2. TD is exempted from
Epidemic disease function lacks, and its T cell function is close to zero, but B cell function is substantially normal；3. no repel during human tumor heterograft
Reaction, therefore it is available for human tumor transplanting.Human tumor after heterograft still keeps its original tissue morphology in nude mice and exempts from
Epidemiology feature and distinctive caryotype and the original responsive type to antineoplastic.Human tumor cells after transplanting still keep
Its original performance.4. nude mice because skin no hair, easy to operate it is easy to dynamically observe the growth conditions of tumour, Vitexin is injected
Agent can suppress human small cell lung carcinoma in the growth of nude mice.
Material：Animal：Nude mice BALB/C/nu.Knurl strain：Human small cell lung carcinoma.Equipment：Operation knife, cut, tweezers, injection
Device, glass homogenizer or trochar, slide measure, superclean bench.Medicine and reagent：Physiology is used before vitexin injection experiment
Salt solution is made into the solution of desired concn, and the solution that front physiological saline is made into desired concn tested by endoxan.
Method：1. take knurl kind and inoculate the human small cell lung carcinoma tumor-bearing mice selecting tumour growth vigorous, at cervical dislocation
Extremely.In the super-clean bench tincture of iodine and alcohol disinfecting animal skin, cut off skin peeling tumour, with homogenizer by tumor tissue plus aseptic life
Cell suspension made by reason salt solution, and it is subcutaneous to be inoculated in animal right upper extremity armpit, and inoculated tumour cell number is about 5 × 104/ only.
2. after packet administration inoculation, packet in the 6th day is administered and measures gross tumor volume.Test sets 5 groups altogether：1. negative control group,
2. endoxan positive drug control group, 3. vitexin injection low dose group 3mg/kg, 4. vitexin injection middle dose group
6mg/kg, 5. vitexin injection high dose group 12mg/kg.Endoxan 60mg/kg lumbar injection 1 time.Vitexin injection
Gastric infusion once a day, continuous 11 days, is discontinued latter 24 hours and puts to death animal, stripping knurl is weighed, and processes number with statistical method
According to carrying out curative effect scoring.
Knurl volume (mm relatively3)=1/2a2B (a is width, and b is length)；
Inhibition rate of tumor growth %=(the average knurl weight of the average knurl weight-administration group of control group) the average knurl weight of/control group ×
100%
Result：It is shown in Table 3 and table 4
The growth inhibition situation (male nude mouse) (x ± s, n=7) of table 3 human small cell lung carcinoma transplanted tumor in nude mice
| Group | Dosage (mg/kg) | Body weight (g) beginning/end | Knurl weight (g) | Inhibiting rate (%) |
| Comparison | -- | 20.8/+4.0 | 3.22±1.598 | -- |
| 5-Fu | 60 | 20.0/+3.0 | 0.12±0.068 | 96.3** |
| Vitexin injection | 3 | 21.1+4.0 | 2.44±1.517 | 24.2 |
| Vitexin injection | 6 | 21.0+2.4 | 1.80±0.492 | 44.1** |
| Vitexin injection | 12 | 20.0+1.8 | 1.45±0.579 | 54.9** |
Note：* P ＜ 0.01
The growth inhibition situation (male nude mouse) (x ± s, n=7) of table 4 human small cell lung carcinoma transplanted tumor in nude mice
| Group | Dosage (mg/kg) | Body weight (g) beginning/end | Knurl weight (g) | Inhibiting rate (%) |
| Comparison | -- | 19.9/+1.3 | 2.89±1.312 | -- |
| 5-Fu | 60 | 19.4/+1.2 | 0.17±0.051 | 94.1** |
| Vitexin injection | 3 | 19.6/+0.9 | 2.02±0.498 | 30.1** |
| Vitexin injection | 6 | 19.9/-0.7 | 1.26±0.658 | 56.4** |
| Vitexin injection | 12 | 20.4/-0.4 | 1.08±0.771 | 62.6** |
Note：* P ＜ 0.01
By table 3, table 4 as can be seen that vitexin injection is in 6mg/kg, 12mg/kg dosage, little to tumor bearing nude mice people thin
Born of the same parents' lung cancer has preferable tumor-inhibiting action, and during 6mg/kg dosage, male mouse tumour inhibiting rate is 44.1% (P ＜ 0.01), and raettin tumour inhibiting rate is
56.4% (P ＜ 0.01)；During 12mg/kg dosage, male mouse tumour inhibiting rate be 54.9% (P ＜ 0.01, raettin tumour inhibiting rate be 62.6% (P
＜ 0.01).
The above is only the preferred embodiment of the present invention it is noted that ordinary skill people for the art
For member, under the premise without departing from the principles of the invention, some improvements and modifications can also be made, these improvements and modifications also should
It is considered as protection scope of the present invention.
Claims (6)
1. the Vitexin with structure shown in Formulas I prevents in preparation and/or treats the application in malignant tumor medicine,
2. application according to claim 1, described malignant tumour includes lung cancer tumor or sarcoma.
3. application according to claim 1, described lung cancer tumor is small cell lung cancer tumor.
4. application according to claim 1, the formulation of described medicine is injection.
5. it is characterised in that described medicine also includes auxiliary material, described auxiliary material includes sweet dew for application according to claim 1
Alcohol, NaOH, hydrochloric acid.
6. application according to claim 1 is it is characterised in that the dosage of described medicine is 3mg/ time～60mg/ time.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610980214.9A CN106420698B (en) | 2016-11-08 | 2016-11-08 | Application of the Vitexin in preparation prevention and/or treatment malignant tumor medicine |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610980214.9A CN106420698B (en) | 2016-11-08 | 2016-11-08 | Application of the Vitexin in preparation prevention and/or treatment malignant tumor medicine |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN106420698A true CN106420698A (en) | 2017-02-22 |
| CN106420698B CN106420698B (en) | 2019-07-23 |
Family
ID=58208031
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610980214.9A Active CN106420698B (en) | 2016-11-08 | 2016-11-08 | Application of the Vitexin in preparation prevention and/or treatment malignant tumor medicine |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106420698B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114790201A (en) * | 2022-05-11 | 2022-07-26 | 陕西中医药大学 | Vitexin derivative and preparation method and application thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103340252A (en) * | 2013-04-10 | 2013-10-09 | 李红章 | Four-season tea body-building health-care beverage |
| CN103735368A (en) * | 2013-12-17 | 2014-04-23 | 张月婵 | Preparation method for sanitary towel containing vitexin |
-
2016
- 2016-11-08 CN CN201610980214.9A patent/CN106420698B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103340252A (en) * | 2013-04-10 | 2013-10-09 | 李红章 | Four-season tea body-building health-care beverage |
| CN103735368A (en) * | 2013-12-17 | 2014-04-23 | 张月婵 | Preparation method for sanitary towel containing vitexin |
Non-Patent Citations (2)
| Title |
|---|
| RASU JAYABALAN等: "Effect of solvent fractions of kombucha tea on viability and invasiveness of cancer cells—Characterization of dimethyl 2-(2-hydroxy-2-methoxypropylidine) malonate and vitexin", 《INDIAN JOURNAL OF BIOTECHNOLOGY》 * |
| 肖崇厚等: "《中药化学》", 30 June 1997, 上海科学技术出版社 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114790201A (en) * | 2022-05-11 | 2022-07-26 | 陕西中医药大学 | Vitexin derivative and preparation method and application thereof |
| CN114790201B (en) * | 2022-05-11 | 2023-11-10 | 陕西中医药大学 | Vitexin derivative and preparation method and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN106420698B (en) | 2019-07-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101716214B (en) | Medical composition containing dandelion extract as well as novel application and preparation method thereof | |
| CN107184911A (en) | One kind is used to prevent cervical carcinoma and treatment papillomavirus（HPV）Infection and the product and preparation method of colpitis | |
| CN105664140A (en) | Glycopeptide composition as well as preparation method and application thereof | |
| CN106726896A (en) | A kind of beautifying health composition with anti-inflammatory bacteriostasis efficacy and preparation method thereof | |
| CN105662996A (en) | Traditional Chinese medicine mask for treating menstruation-associated acne | |
| CN102716407A (en) | Application of amomum tsao-ko oil on preparing medicaments with functions of restraining or killing candida albicans | |
| CN106420698B (en) | Application of the Vitexin in preparation prevention and/or treatment malignant tumor medicine | |
| CN105287692A (en) | Dalbergia benthami prain extractive, and preparation method and application thereof | |
| CN108186718A (en) | A kind of gynaecology's spray prevented and inhibit HPV viruse | |
| CN104940241B (en) | A kind of selenium worm grass compound preparation of prevention climacteric metancholia of women | |
| US20020197341A1 (en) | Physiologically synergistic mixtures of pomegranate extracts and methods of use thereof | |
| CN106620633A (en) | Skin repairing cream for tumor patients and preparation method of skin repairing cream | |
| CN102283988A (en) | Preparation method for traditional Chinese medicine capable of enhancing antineoplastic activity of patient and leaching liquor thereof | |
| CN106389477B (en) | A kind of preparation method and application of the full cellular plant oil extract of Gordonia terrae | |
| CN106389329A (en) | Dipyridamole oral emulsion administration system and preparation method thereof | |
| CN105560620A (en) | Trauma treatment traditional Chinese medicine preparation | |
| CN108324648A (en) | A kind of composition of anti-acne | |
| CN104799289A (en) | Compound nutritious food with antineoplastic and immunity enhancement functions and production method for compound nutritious food antineoplastic and immunity enhancement functions | |
| CN105902561A (en) | Application of Gracilariopsis lemaneiformis polysaccharide as antitumor chemotherapy drug synergist and antitumor drug | |
| CN106420483A (en) | Skin-clearing blackhead dissolving solution | |
| CN102670735A (en) | Anti-dandruff Chinese medicinal composition and application thereof to anti-dandruff external application agent | |
| CN103599437B (en) | One treats colpitic traditional Chinese medicine liquid | |
| CN102949712A (en) | Chinese and western composite medicine for treating neoplastic diseases | |
| CN101797280B (en) | Anti-aging traditional Chinese medicinal preparation | |
| CN104825744A (en) | Traditional Chinese medicine gel for treating vaginitis as well as preparation method and application of traditional Chinese medicine gel |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |